BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (Nasdaq: CLVS) announced today the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a price to the public of $57.50 per share. All of the shares are being sold by certain existing stockholders who acquired the shares of the Company’s common stock as consideration in connection with the Company’s acquisition of EOS (Ethical Oncology Science) S.p.A.
Help employers find you! Check out all the jobs and post your resume.
